Abstract
In The Lancet Oncology, B Ashleigh Guadagnolo and colleagues1 report the early results of a single-arm, single-centre, prospective trial (HYPORT-STS) evaluating a moderately hypofractionated regimen of preoperative radiotherapy (42·75 Gy in 15 fractions of 2·85 Gy/day for 3 weeks [five fractions per week]) in patients with soft tissue sarcomas of the extremities or trunk. The authors chose the landmark CAN-NCIC-SR2 trial2,3 for comparison in the absence of randomisation and strictly defined their primary endpoint of major wound complications within 120 days of surgery consistently with the comparative trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
